Physician profile
Ali A Bazzi
NPI 1477553063
$25,050.22
in general payments reported to CMS, 2019-2025
42 companies · $3,013 in 2025
The $3,013 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,067 · 2020: $4,739 · 2021: $8,424 · 2022: $2,450 · 2023: $1,780 · 2024: $2,578 · 2025: $3,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,744 · Travel and Lodging: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,744.44 |
| Travel and Lodging | $626.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $9,536.15 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $6,359.55 | 2021-2025 | Mycarelink, Micra, Cobalt Dr Mri Surescan |
| Boston Scientific Corporation | $2,592.77 | 2019-2025 | Watchman Access System, Watchman Flx, Farapulse |
| Medtronic Vascular, INC. | $766.15 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $725.97 | 2019-2024 | Xarelto |
| Pfizer INC. | $709.65 | 2019-2025 | |
| Abbott Laboratories | $432.15 | 2019-2025 | Navitor, Amplatzer Talisman |
| Astellas Pharma US INC | $395.04 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $392.31 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $305.60 | 2019-2024 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.98 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $290.72 | 2019-2025 | Wainua, Farxiga |
| Novartis Pharmaceuticals Corporation | $266.98 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $161.29 | 2019 | |
| Shockwave Medical, INC | $147.79 | 2021 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $135.10 | 2021-2025 | Verquvo |
| Akcea Therapeutics, INC. | $134.40 | 2019 | |
| Heartflow, INC. | $131.24 | 2023-2025 | Ffrct |
| Cvrx, INC. | $125.14 | 2022-2024 | Barostim Neo System |
| Amarin Pharma, INC. | $123.88 | 2019-2021 | |
| Philips North America LLC | $105.27 | 2020-2023 | |
| Irhythm Technologies, INC. | $99.47 | 2019-2024 | Zio Xt Patch, Zio Monitor |
| Baxter Healthcare | $97.62 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $77.52 | 2022-2025 | |
| Esperion Therapeutics, INC. | $66.69 | 2020-2025 | Nexletol |
| Angiodynamics, INC. | $56.57 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $56.01 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $53.63 | 2019 | |
| Alnylam Pharmaceuticals INC. | $49.75 | 2021-2023 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $42.79 | 2022-2025 | Opsumit, Uptravi |
| Bardy Diagnostics, INC. | $40.00 | 2020-2022 | |
| Abiomed | $37.11 | 2024 | Impella |
| Novo Nordisk INC | $33.25 | 2021-2024 | Wegovy |
| Bridgebio Pharma, INC. | $32.16 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $30.36 | 2025 | Assure Wcd |
| Edwards Lifesciences Corporation | $29.67 | 2024 | |
| Terumo Medical Corporation | $20.93 | 2021 | |
| Glaxosmithkline, LLC. | $19.92 | 2025 | Arexvy, Shingrix |
| Aegerion Pharmaceuticals, INC. | $19.26 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $17.87 | 2023 | Arcalyst |
| Genzyme Corporation | $15.79 | 2023 | |
| Arbor Pharmaceuticals, INC. | $14.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Bazzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.